You may have read the recent editorial from Cigar Aficionado, which did not fully reflect the substance of Altria’s comments on the Food & Drug Administration’s Advance Notice of Proposed Rulemaking (ANPRM) on the Regulation of Premium Cigars. I wanted to offer my perspective by providing my colleagues and friends in the industry with additional context on Altria’s comments.
I urge you to read the letter, and our comments, in their entirety and come to your own informed opinion about the company’s commitment to the premium cigar industry.
You might also want to read John McTavish’s blog, which was posted on July 31 and gives a very informed perspective on Altria’s ANPRM comments:
Vice President, Retail and Brand Development, Nat Sherman International